Ratiopharm alleges that the claims in issue regarding the > 274 Patent are claims for an intermediate and not claims for a medicine and thus, pursuant to Eli Lilly v. Apotex (1995) 63 C.P.R. (3d) 245, are not eligible for listing under the NOC Regulations. Abbott asserts that they are claims for a medicine within the meaning of the NOC Regulations.
"The most advanced legal research software ever built."
The above passage should not be considered legal advice. Reliable answers to complex legal questions require comprehensive research memos. To learn more visit www.alexi.com.